@ERNEuroBloodNet is enormously glad about the progress of the projects that are being developed in the frame of the network! Thank you so much to the speakers who presented part of them to the #EHA2023 audience! Together we are stronger!
#ERNeu#EU4Health#ShareCareCure
2020 SOHO Update on AML in Older Patients at MD Anderson: Therapy Intensity, Maintenance Therapy, TP53-Mutated AML, Secondary AML | VuMedi https://t.co/TofTHcZuYv via @vumedi
La risposta dell'IRST IRCCS all'emergenza Covid19 nelle testimonianze di pazienti, medici, direttori e operatori che più direttamente hanno vissuto e continuano a vivere, questa condizione.
https://t.co/LM7BKYn3IE
#Nanotecnologie vs #tumori: ricercatori del CdO-TR-TC IRST #IRCCS sviluppano nuovo #farmaco per aggredire il #microambiente che accoglie le neoplasie. La sfida è il passaggio dal "in vitro" alla clinica.
👉 https://t.co/Ya21eQMw2U
NTRK is here in lung and other many tumors🎺🎺. We MUST screen 🧬as we have very effective drugs 🎯 regardless of tumor types.Are all NTRK inhibitors equal? We aware about neurologic side effects in this pts (dizziness, pain, ⬆️ weight..)Repotrectinib at PD #ESMO2020#LCSM#NTRK
Expertise in Leukemia: Giovanni Martinelli https://t.co/mYkqkWeUSu
Non e' mai facile provare un "esperto" in un dato settore della medicina ad esempio la #leucemiaacuta per chiedere una "#secondaopinione"...
L’Irst sta conducendo un trial clinico approvato da Aifa con idrossiclorochina in covid asintomatici e covid contact chiamato Protect.
#irst#vicinoachicura
In today’s late breaking abstract session at @EHA_Hematology Virtual, Courtney DiNardo presents results of the phase 3 RCT testing venetoclax plus azacitidine vs azacitidine in patients with AML ineligible for intensive therapy (VIALE-A) #EHA2020
Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome - Full Text View - https://t.co/yFB4njBNLI https://t.co/hC6QRh6qbV